Within 48 hours, The BMJ published an article written by a staff journalist, which claimed that the new study "was based on flawed analysis." 3 Zosia Kmietowicz had contacted Mark Jones, University of Queensland, who is working with the Cochrane Collaboration on another project related to neuraminidase inhibitors. In turn, Jones had provided a detailed statistical critique of the PRIDE study, which formed the centrepiece of Kmietowicz's article. The PRIDE Consortium was not forewarned about the article and, more importantly, not offered any a priori right of reply, as would normally be the case during post-publication correspondence. Faced with such a one sided critique of its work, the PRIDE Consortium had no option but to post its initial rebuttal in The BMJ. 4 There has since been a further critique from Jones and a further statistical rebuttal from the PRIDE Consortium. 5 6 Thus, the correspondence and debate relating to a major publication in a Lancet Group paper has been played out in the pages of The BMJ, fronted by an entirely one sided article from a staff journalist on The BMJ. The major question here seems to be the propriety of The BMJ and Dr Jones in going beyond the reasonable response to a press release, by asking potential opponents for a detailed statistical critique without offering the authors of the study any right to reply alongside. A more conventional and considerably more ethical approach would have been to submit correspondence post-publication to the Lancet Respiratory Medicine, which could then have considered the response in the normal way, including offering the PRIDE Consortium a realistic period of time to consider the critique and write a rejoinder.
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